Acción NBIX NEUROCRINE BIOSCIENCES, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Neurocrine Biosciences, Inc.

Acciones

NBIX

US64125C1099

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 26/04/2024 		Varia. Cinco días. Varia. 1 de enero.
136 USD -1,28 % Gráfico intradía de Neurocrine Biosciences, Inc. +3,02 % +3,21 %
24/04 NEUROCRINE BIOSCIENCES, INC. : El Wells Fargo Securities actualiza su recomendación a compra ZM
24/04 Neurocrine Biosciences, Inc. ¡lanza la iniciativa educativa What the C@H! Iniciativa educativa para apoyar a la comunidad de la hiperplasia suprarrenal congénita CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Neurocrine Biosciences Launches WHAT THE C@H Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test
Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing
Neurocrine Biosciences to Participate at Investor Conferences in March
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción NBIX
  4. Noticias Neurocrine Biosciences, Inc.
  5. Otros idiomas